Risvodetinib is a small molecule commercialized by Inhibikase Therapeutics, with a leading Phase II program in Parkinson’s Disease. According to Globaldata, it is involved in 5 clinical trials, of which 1 was completed, 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Risvodetinib’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Risvodetinib is expected to reach an annual total of $42 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Risvodetinib (Ikt-148009) is under development for the treatment of Parkinson’s disease (PD), dysphagia, neurogenic constipation and multiple system atrophy. The drug candidate is administered orally. It acts by targeting Abelson tyrosine kinase (BCR-ABL) enzyme and ABL1 (c-Abl). It is developed based on Re-engineering Approach with Metabolism Preserved (RAMP) technology.
Inhibikase Therapeutics Overview
Inhibikase Therapeutics is a biotechnology business dedicated to the development and commercialization of small-molecule kinase inhibitor therapeutics for the safe and effective treatment of neurological illnesses both inside and outside the brain. The company is headquartered in Atlanta, Georgia, the US.
The company reported revenues of (US Dollars) US$0.1 million for the fiscal year ended December 2022 (FY2022), a decrease of 96% over FY2021. The operating loss of the company was US$18.1 million in FY2022, compared to an operating loss of US$14.8 million in FY2021. The net loss of the company was US$18.1 million in FY2022, compared to a net loss of US$14.8 million in FY2021.
For a complete picture of Risvodetinib’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.